Richard Chin, M.D., is the former CEO of OneWorld Health (acquired by PATH in 2011), a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. OneWorld Health is a leader in global health and neglected diseases, including its breakthrough work on low-cost semisynthetic artemisinin for malaria.
Dr. Chin a Harvard-trained physician and has extensive drug development experience, including multiple drug approvals and launches. He also holds the equivalent of a J.D. from Oxford, where he studied as a Rhodes Scholar. He was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs. Dr. Chin serves as Associate Professor at UCSD and is the author of several major textbooks on clinical development. He serves on boards of several biotechnology companies.
Currently, Dr. Chin is engaged in a starting up a biotech company with a novel approach to drug development.